Search

Your search keyword '"123I-FP-CIT"' showing total 32 results

Search Constraints

Start Over You searched for: Descriptor "123I-FP-CIT" Remove constraint Descriptor: "123I-FP-CIT" Database MEDLINE Remove constraint Database: MEDLINE
32 results on '"123I-FP-CIT"'

Search Results

1. Clinical assessment and striatal dopaminergic activity in healthy controls and patients with Parkinson's disease: a Bayesian approach.

2. Comparison of the ability of different quantitative indices in 123 I-FP-CIT single-photon emission computed tomography to differentiate dopaminergic neurodegenerative disease.

3. Verification of optimal conditions for the scattering correction of 123 I-FP-CIT SPECT on a single-photon emission tomography system with a two-detector whole-body cadmium-zinc-telluride semiconductor detector.

4. Association between longitudinal changes in striatal dopamine transporter uptake and clinical features of dementia with Lewy bodies.

5. No impact of attenuation and scatter correction on the interpretation of dopamine transporter SPECT in patients with clinically uncertain parkinsonian syndrome.

6. Evaluation of Collimators in a High-Resolution, Whole-Body SPECT/CT Device with a Dual-Head Cadmium-Zinc-Telluride Detector for 123 I-FP-CIT SPECT.

7. Role of Functional Neuroimaging with 123I-MIBG and 123I-FP-CIT in De Novo Parkinson's Disease: A Multicenter Study.

8. Effect of cerebrospinal fluid area mask correction on 123 I-FP-CIT SPECT images in idiopathic normal pressure hydrocephalus.

9. Striatal Dopaminergic Depletion Pattern Reflects Pathological Brain Perfusion Changes in Lewy Body Diseases.

10. Convolutional neural network based attenuation correction for 123 I-FP-CIT SPECT with focused striatum imaging.

11. A diagnostic strategy for Parkinsonian syndromes using quantitative indices of DAT SPECT and MIBG scintigraphy: an investigation using the classification and regression tree analysis.

12. Multi-Atlas MRI-Based Striatum Segmentation for 123 I-FP-CIT SPECT (DAT-SPECT) Compared With the Bolt Method and SPECT-Atlas-Based Segmentation Method Toward the Accurate Diagnosis of Parkinson's Disease/Syndrome.

13. Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies.

14. Effect of sex on aging-related decline of dopamine transporter in healthy subjects.

15. Case Report: The Role of Neuropsychological Assessment and Imaging Biomarkers in the Early Diagnosis of Lewy Body Dementia in a Patient With Major Depression and Prolonged Alcohol and Benzodiazepine Dependence.

16. Quantification and discriminative power of 18 F-FE-PE2I PET in patients with Parkinson's disease.

17. Continuous Repetitive Data Acquisition with 123 I-FP-CIT SPECT: Effects of Rotation Speed and Rotation Time.

18. Impact of the cerebrospinal fluid-mask algorithm on the diagnostic performance of 123 I-Ioflupane SPECT: an investigation of parkinsonian syndromes.

19. Impact of a combination of quantitative indices representing uptake intensity, shape, and asymmetry in DAT SPECT using machine learning: comparison of different volume of interest settings.

20. A Japanese Encephalitis Patient Presenting with Parkinsonism with Corresponding Laterality of Magnetic Resonance and Dopamine Transporter Imaging Findings.

21. Head-to-head comparison of 18 F-FP-CIT and 123 I-FP-CIT for dopamine transporter imaging in patients with Parkinson's disease: A preliminary study.

22. The Utility of the Combined Use of 123 I-FP-CIT and 123 I-MIBG Myocardial Scintigraphy in Differentiating Parkinson's Disease from Other Parkinsonian Syndromes.

23. Quantitative evaluation of the tracer distribution in dopamine transporter SPECT for objective interpretation.

24. Improvement in the measurement error of the specific binding ratio in dopamine transporter SPECT imaging due to exclusion of the cerebrospinal fluid fraction using the threshold of voxel RI count.

25. Lower 123 I-FP-CIT binding to the striatal dopamine transporter, but not to the extrastriatal serotonin transporter, in Parkinson's disease compared with dementia with Lewy bodies.

26. Correlations between dopamine transporter density measured by 123 I-FP-CIT SPECT and regional gray matter volume in Parkinson's disease.

27. Correlation between clinical symptoms and striatal DAT uptake in patients with DLB.

28. Optimization of Reformatting Angle Using Orbitomeatal Base Line in Dopamine Transporter Scintigraphy.

29. Brain (18)F-FDG, (18)F-Florbetaben PET/CT, (123)I-FP-CIT SPECT and Cardiac (123)I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease.

30. Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease.

31. Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia.

32. Value of semiquantitative analysis for clinical reporting of 123I-2-β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)nortropane SPECT studies.

Catalog

Books, media, physical & digital resources